Florastor® Reduces Diarrhea from H. pylori Therapy

Florastor’s proprietary strain, Saccharomyces boulardii CNCM I-745, survives and thrives during H. pylori antibiotic therapy, helping to improve health outcomes and enhance patient compliance.

Systematic reviews and meta-analyses consistently demonstrate Florastor as an essential addition to H. pylori treatment plans:

  • Reduced Adverse Events: Florastor, S. boulardii CNCM I-745, helps minimize common gastrointestinal side effects of H. pylori antibiotic therapy, such as diarrhea.
  • Supports Antibiotic Therapy: Florastor, being resistant to antibiotics, helps maintain gut health and supports H. pylori treatment by promoting a balanced intestinal microbiota in both adult and pediatric patients.
  • Improved Patient Adherence: By reducing side effects, Florastor supports better patient adherence to the treatment regimen.

Incidence of diarrhea with Hp eradication therapy in patients receive in Florastor + Hp eradication vs. Hp eradication alone13

In an open-label, prospective, randomized trial of adult patients with confirmed Hp infection, patients received:

  • Sequential treatment alone ( 10 days of omeprazole + antibiotics), n=99
  • Sequential treatment + Florastor (250mg bid), n=100

Learn How Florastor is the Perfect Complement to Antibiotics

Read More

Welcome to the Florastor® site for Healthcare Professionals

Are you a health care professional?

No

By indicating that I am a Health Care Professional, I acknowledge: